A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 26 May 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Gliclazide
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 19 May 2017 Planned End Date changed from 1 May 2018 to 1 Oct 2018.
- 19 May 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2018.